$RPRX

Royalty Pharma (RPRX) reported that pelacarsen failed its Phase 3 trial, shifting financial focus to Spinraza royalties. The company provided $500M to Ionis (IONS) in 2023, with $150M allocated to pelacarsen. RPRX expects to recover its investment through Spinraza, aiming for a modest return. The failure limits pelacarsen's potential upside, and recovery depends on Spinraza's performance.

Novartis AG (NYSE:NVS) stock fell sharply after its Phase 3 HARBOR trial for del-desiran in myotonic dystrophy type 1 missed the primary endpoint. The company also reported that the pelacarsen Phase 3 Lp(a)HORIZON trial for cardiovascular outcomes failed. Both Ionis Pharmaceuticals (NASDAQ:IONS) and Royalty Pharma (NASDAQ:RPRX) saw stock declines due to their ties with Novartis.

Novartis (NYSE:NVS) stock fell sharply after Phase 3 HARBOR trial for del-desiran in myotonic dystrophy type 1 missed primary endpoint. The company also reported that the pelacarsen cardiovascular trial failed to meet its primary endpoint. Ionis Pharmaceuticals (NASDAQ:IONS) and Royalty Pharma (NASDAQ:RPRX) shares also declined due to the trial results. Novartis is evaluating the data and plans to discuss next steps with health authorities.

Royalty Pharma (RPRX) updated on Novartis' Phase 3 trial for pelacarsen, which failed to meet its primary endpoint. Despite this, RPRX expects to recoup its $500M investment and earn a modest return. The company reiterated its 2030 Portfolio Receipts target of $4.7B+.

Several biotech stocks hit 52-week highs on September 1, 2026. MiniMed Group (MMED) rose 10% to $22.74 with 16.6% sales growth. Pulse Biosciences (PLSE) gained 3% to $54.39. Solventum (SOLV) reached $94.16 with 2.2% revenue growth. Royalty Pharma (RPRX) climbed to $62.58 with 14% royalty receipts growth. Apogee Therapeutics (APGE) hit $135.09 and will be acquired by AbbVie for $10.9B.

Royalty Pharma (RPRX) agreed to pay Zealand Pharma $100M for future royalties on rusfertide, an experimental treatment for polycythemia vera. The deal includes a 1% royalty on global sales, with $50M paid at closing and the rest after a year. Rusfertide's FDA decision is expected in Q3 2026. RPRX's Q2 2026 royalty receipts grew 14% to $768M, and it raised its full-year guidance to $3.4B-$3.5B. The company has $9.2B in debt and expects $350M-$360M in interest payments for 2026.

Royalty Pharma (RPRX) agreed to a $100M deal with Zealand Pharma for rights to a rare blood disorder therapy. RPRX shares are down 1.86% to $60.58, but up 11.16% over 90 days and 70.08% over a year. Analysts debate its valuation, with some calling it 2% overvalued at $59.25, while a DCF model suggests it's heavily discounted at $195.31.

Royalty Pharma (RPRX) EVP & Chairman Christopher Hite sold 100,000 shares via a 10b5-1 plan at $59.9725 each, leaving 370,401 indirectly held. He also donated 16,800 shares to Lehigh University, retaining 23,200 directly. Family vehicles hold convertible interests.

Hite Christopher (EVP & Chairman, Partnering) sold 100,000 indirectly-held shares of Royalty Pharma plc (RPRX) at $59.97 ($6.00M total) on 2026-08-18 under a Rule 10b5-1 trading plan.

Coyne Terrance P. (EVP & CFO) sold 11,002 indirectly-held shares of Royalty Pharma plc (RPRX) at an average of $58.68 ($58.59–$59.14, $0.65M total) across 2 trades on 2026-08-13 under a Rule 10b5-1 trading plan.